Latest News

Advocacy through groups like BCAN and the AUA shapes urologic oncology policy—driving funding, screening access, and equity in cancer care, the authors write.

The Zenflow Spring Implant and Delivery System has entered commercial use for BPH following its FDA approval in December 2025.

Scammers are stealing female urologists' headshots to run AI-driven catfishing and supplement scams; in this article, 2 urologists share their experiences with this concerning trend.

Rising patient interest in TRT, GLP-1s, and peptide stacking requires clinicians to anchor conversations in evidence tiers, use baseline DEXA scans to monitor body composition, and engage patient goals without endorsing unsupported claims.

Higher saturated and animal fat intake was linked to increased mortality after nonmetastatic prostate cancer, according to a cohort study published in JAMA Network Open.

In this episode, Surena F. Matin, MD, FACS, discusses the evidence and practical considerations surrounding perioperative intravesical chemotherapy to reduce bladder recurrence after nephroureterectomy.

The FDA has provided an update on efforts to increase supply of estradiol transdermal patches as demand increases.

NeoBLAST, a phase 2/3 Canadian trial, tests whether active surveillance can safely replace surgery/radiation in MIBC patients with complete response to neoadjuvant therapy.

This episode explores evolving approaches to sexual wellness, innovation in premature ejaculation, the need for patient education, and integrating sexual health products into clinical care across the lifespan.

In this Q&A, Shiv B. Patel, MD, reflects on how prostate cancer screening has evolved from a one-size-fits-all approach to a more individualized strategy.

The target enrollment goal has been reached in the phase 3 BiPASS study, evaluating PSMA-PET plus MRI for prostate cancer detection.

Routine cardiovascular specialist referral improved cholesterol control in patients with prostate cancer but did not reduce cardiovascular events.

LUGPA CEO Celeste Kirschner, CAE, MHSA, outlines the association's top 2027 priorities: fee schedule reform, site-neutral payments, prior authorization, and practice consolidation.